Lloyd Brown MD FACS

Lloyd Brown MD FACS Website to be launched August 2021| To be added to my mailing list send an email to me at lloydbrown

06/25/2025

In the first FDA-approved human clinical trial of its kind, Dr. Vipul Patel performed surgery on a patient in Angola.

ILLS 2025 is underway in Seoul, South Korea!Today marks Day 1 of the 5th World Congress of the International Laparoscopi...
06/25/2025

ILLS 2025 is underway in Seoul, South Korea!
Today marks Day 1 of the 5th World Congress of the International Laparoscopic Liver Society and the 3rd International Consensus Conference on Minimally Invasive Liver Resections.

Surgeons, scientists, and innovators from around the world are gathered to share advances and shape the future of minimally invasive liver surgery. Follow along for insights and updates from !
🔗 www.ills2025.com

COEX is Asia's largest and leading conference & exhibition venue, converniently connected to the World Trade Tower, City Air Terminal, shopping mall, and hotels. Surrounded by the wide avenues in the Southern Seoul, it creates the most efficient and comfortable convention atmosphere for all meetings...

Looking forward to all there is to learn on this trip.
06/16/2025

Looking forward to all there is to learn on this trip.

The International Laparoscopic Liver Society (ILLS) will host its 5th World Congress from June 24–27, 2025 at COEX in Seoul, South Korea, alongside the 3rd International Consensus Conference on Minimally Invasive Liver Resections.

This global meeting brings together surgeons, innovators, and thought leaders at the forefront of laparoscopic and robotic-assisted liver surgery. It’s a unique opportunity to exchange insights on surgical technique, program building, and emerging evidence in minimally invasive HPB and transplant approaches.

Topics will include:
• Advanced robotic techniques in liver resection
• Complex case strategies using minimally invasive platforms
• Outcomes data and evolving consensus
• Training models and capacity-building strategies

For those working in hepato-pancreato-biliary (HPB) surgery, transplantation, or expanding robotic programs, ILLS 2025 offers focused, high-value content.

🔗 Learn more: www.ills2025.com

HepatoBiliary and Liver Transplant Surgeons like myself can attest that early intervention can change the trajectory of ...
05/24/2025

HepatoBiliary and Liver Transplant Surgeons like myself can attest that early intervention can change the trajectory of these complications and get patients back on the road of recovery quickly. We are all in this together.

Researchers at the University of Pittsburgh are breaking new ground in liver care with mRNA therapies aimed at rejuvenat...
11/17/2024

Researchers at the University of Pittsburgh are breaking new ground in liver care with mRNA therapies aimed at rejuvenating damaged livers. This cutting-edge technology could one day reduce the need for organ transplants, offering a less invasive and more accessible alternative. Clinical trials are expected to begin next year. Learn more about this groundbreaking work here: https://www.wired.com/story/mrna-organ-rejuvenation-pittsburgh-upmc-center-transcriptional-medicine/?utm_source=chatgpt.com

Researchers are testing the use of mRNA to get damaged livers to repair themselves, in a move that could one day lessen the need for organ transplants.

11/17/2024

Fun Fact #416:
Have you ever wondered where the word “liver” comes from? Its origins trace back to the Old English lifere and Proto-Germanic librō, meaning “to live.” In ancient times, the liver was considered the source of vitality and life itself—a belief that persists in the organ’s symbolic significance today.

11/02/2024

I encourage all AHPBA fellows conducting Humanitarian Medical Outreach and Capacity Building to submit applications for this Award.

Marburg Virus Outbreak in Rwanda: Vaccines and Therapeutics UpdateStarting this Sunday, October 6th, Rwanda will begin v...
10/06/2024

Marburg Virus Outbreak in Rwanda: Vaccines and Therapeutics Update

Starting this Sunday, October 6th, Rwanda will begin vaccinating frontline healthcare workers and those at high risk against the Marburg virus, as part of the country’s intensified response. According to the Rwandan Ministry of Health, the latest figures confirm 46 cases and 12 deaths.

Therapeutics in use include:

• Remdesivir by Gilead Sciences, an antiviral targeting the virus’s replication apparatus. This drug has been used in Ebola with limited efficacy and has also been utilized in the treatment of COVID-19.
• MBP-091, an experimental monoclonal antibody from Mapp Biopharmaceutical, designed to neutralize the virus and assist the patient’s immune system in fighting back.

For more information on the vaccines and treatments being deployed, read the full article: Marburg Virus Therapeutics in Rwanda.

There are currently no licensed vaccines or drugs to prevent or treat Marburg, but experimental versions are heading to Rwanda.

10/05/2024

Understanding the Marburg Virus Outbreak in Rwanda: Reflections, Facts, Key Methods, and Symptoms

As many of you are aware, Rwanda is currently facing an outbreak of the Marburg virus, a highly infectious disease in the same family as Ebola. Given the nature of the virus and its potential impact, I want to share some brief reflections, along with key facts and principles, to help clarify the situation and avoid unnecessary panic or misinformation.

As you may know, I have a fondness and connection with Rwanda. I have traveled there many times to collaborate on capacity building in transplant surgery and increasingly in hepatobiliary (HPB) surgery (liver surgery). I have made friends there, and whenever something happens in Rwanda, especially in Kigali, the capital where I have spent a lot of time, my thoughts immediately go to them.

My heart goes out to those who have lost loved ones and colleagues thus far. I have personally worked with the amazing healthcare staff at King Faisal Hospital and the University Teaching Hospital of Kigali (CHUK), and I can only imagine the pain they must feel at the sudden loss of their dedicated, selfless, and courageous colleagues who have succumbed to this disease while serving others.

With them in mind, I would like to ensure no misinformation is put forth. I know that Rwanda has a robust, well-organized healthcare sector, and the Ministry of Health, its ministers, and staff are quite capable. I look forward to the full resolution of this outbreak and to returning many more times to the ‘Land of a Thousand Hills’ and its beautiful people in the future.

Known Facts:

• Marburg virus disease (MVD) is a severe viral hemorrhagic fever with a fatality rate ranging from 24% to 88%, depending on the virus strain and case management.
• As of October 4th, 2024, Rwanda has reported 41 confirmed cases and 12 deaths.
• The Rwandan government, in collaboration with WHO and CDC, has been swift in implementing isolation and decontamination measures to contain the outbreak. Daily updates are provided on their websites and social media.
• The virus has an incubation period of 2-21 days, meaning it can take up to 21 days for an exposed person to show symptoms.
• No licensed treatment is currently available to neutralize the virus, but experimental treatments and vaccines are in development.

Epidemiological Principles: What Is Being Done

1. Containment: The primary focus is isolating infected individuals and conducting thorough contact tracing to find anyone exposed to the virus. Rwanda is actively applying these methods, and there has been no confirmed international spread as of now.
2. Case Fatality Rate (CFR): Marburg’s CFR can range between 50-90%, making it one of the more lethal viruses. It is crucial to focus on reducing the spread rather than assuming all exposed individuals will be infected.
3. R0 (Reproduction Number): This represents how many people, on average, one infected person can pass the virus to. If the R0 is greater than 1, the outbreak can grow. Reducing the R0 through isolation and quarantine is key to stopping the spread.

Symptoms of Marburg Virus Disease (Source: WHO):

• Initial symptoms: High fever, severe headache, severe malaise, muscle aches, and pains.
• Day 3 symptoms: Severe watery diarrhea, abdominal pain, cramping, nausea, and vomiting. Diarrhea can last for a week.
• Between Days 5 and 7: Many patients develop severe hemorrhagic symptoms, with bleeding from multiple areas, such as the nose, gums, and even venepuncture sites.
• Severe cases: Central nervous system involvement can lead to confusion, irritability, and aggression.
• Fatal cases: Death usually occurs between 8 and 9 days after the onset of symptoms, often due to severe blood loss and shock.

For more details on Marburg symptoms and general information, you can check the WHO fact sheet here: https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease.

Caution Against Speculation:

It’s important to avoid speculating on the spread of the virus without factual evidence. As we learned early in the COVID-19 pandemic, misinformation can cause more harm than good. In addition there is always opportunists who will render biased opinions without merit.

Current data from Rwandan authorities, WHO, and CDC show that containment efforts are underway. We should focus on supporting these measures and staying informed through trusted sources.

Follow more updates here:

• WHO: https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease
• CDC: https://www.cdc.gov/vhf/marburg/index.html
• Rwandan Ministry of Health: http://www.rbc.gov.rw

Mini Glossary:

• Incubation Period: The time from exposure to the virus to the onset of symptoms (2-21 days for Marburg).
• Case Fatality Rate (CFR): The percentage of people who die after becoming infected.
• R0 (Reproduction Number): A measure of how many people one infected person can spread the virus to.

Facebook links:

• WHO Facebook: https://www.facebook.com/WHO/
• CDC Facebook: https://www.facebook.com/CDC/



Poll:

1. Do you feel more informed about the current Marburg virus outbreak in Rwanda?
• Yes
• No

This is the World Health Organization (WHO) official page. Join the conversation!

10/04/2024

Liver Transplantation Hot Topic: Read Now

There are unique challenges of living donor , particularly for those with alcohol-associated hepatitis. https://bit.ly/47u3nqr

Reflections from TTS 2024: New Milestones in Global TransplantationNow that  has closed, I wanted to share some takeaway...
09/28/2024

Reflections from TTS 2024: New Milestones in Global Transplantation

Now that has closed, I wanted to share some takeaways from this meeting especially a session discussing the World Health Assembly’s resolution:

“Increasing availability, ethical access, and oversight of transplantation of human cells, tissues, and organs.”

This resolution signifies a global commitment to advancing ethical transplantation practices and ensuring life-saving procedures are available to those who need them.

Here’s a link to the full resolution: https://apps.who.int/gb/ebwha/pdf_files/EB154/B154(7)-en.pdf.

The European Society for Organ Transplantation (ESOT) also released an announcement highlighting the significance of this resolution for the global community: https://esot.org/new-resolution-adopted-by-the-world-health-assembly/.

The discussions at TTS 2024 have been thought-provoking, emphasizing the importance of collaboration and innovation in transplant surgery. I am also very much in tuned to the ethical considerations in terms of donor protection. Enough cannot be said about this issue.

I’m glad I attended the sessions om capacity building in particular and being a part of this ongoing dialogue. I have gained more and indent perspectives especially as it relates to Low and Middle Income Countries (LMICs) where this takes on a different dimension.

Outside of my work as a transplant surgeon in Chicago, I work in these LMIC settings, especially on the continent of Africa and increasingly so pivoting to the Caribbean where there is still significant lack of capacity and regulation.

I’m looking forward to contributing to the efforts toward more equitable access to transplantation services.

Stay tuned for more reflections going forward as I am committed to staying engaged.

Transforming Transplantation in Rwanda through CollaborationOur team has been working to establish a sustainable kidney ...
09/28/2024

Transforming Transplantation in Rwanda through Collaboration
Our team has been working to establish a sustainable kidney transplant program in Rwanda, with collaboration at the heart of our efforts. Moving away from the traditional “mission” model, we’ve partnered with local institutions and U.S. universities (including Mount Sinai, Rush, University of Michigan) to create a lasting impact. By engaging the Ministry of Health and other key stakeholders, this approach is set to shape transplantation capacity in Rwanda and beyond.

Key points:

• Multidisciplinary and multi-institutional collaboration.
• Sustainable, long-term approach to kidney transplantation.
• Partnership with local government, universities, and international institutions.
• A model for capacity building in low-income countries.

https://journals.lww.com/transplantjournal/fulltext/2024/05000/establishing_a_kidney_transplantation_program_in_a.1.aspx

Address

East Orange, NJ

Alerts

Be the first to know and let us send you an email when Lloyd Brown MD FACS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Lloyd Brown MD FACS:

Share

Category